Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hangzhou Choutu Technology is a medical AI and biophotonics company specializing in stain-free digital pathology and automated tissue analysis. Founded in 2014 as the China subsidiary of Singapore-based HistoIndex, the company provides the Genesis®200 imaging system, which utilizes Second Harmonic Generation (SHG) and Two-Photon Excitation Fluorescence (TPEF) to quantify fibrosis and other morphological features without chemical staining. Its proprietary AI software, including HistoHepa™ and FibroSIGHT™, enables high-precision, objective assessment of collagen and architectural markers to support drug development and clinical diagnosis for conditions such as NASH and MASH. Choutu Technology partners with global pharmaceutical companies, CROs, and research institutions to provide quantitative endpoints for clinical trials and preclinical studies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hangzhou Choutu Technology.